Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Consonance CapMan GP LLC on 11 October 2017.
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the establishment of Ablynx, Inc., its subsidiary in the USA, and the appointment of Mr Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America. Mr Daniel (Dan) Schneider will be based in a US office, to be located on the East Coast. Caplacizumab is the Company's wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the completion of recruitment in the E4 Relief Phase II study of Donesta®, Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4) for Vasomotor Menopausal Symptoms (VMS) relief. Top-line data, based on 12-weeks of treatment, remain on track to be reported late in the first quarter of 2018.
Led by Jean-Christophe Marine (VIB-KU Leuven), a team of researchers has tracked down the cellular origin of cutaneous melanoma, the deadliest form of skin cancer. The team was surprised to observe that these very aggressive tumors arise from mature, pigment-producing cells called melanocytes. As melanoma develops, these cells are eventually reprogrammed, lose their differentiated features and become invasive, migratory cancer cells. This knowledge is vital to understand how these melanoma lesions are formed, facilitate their early detection and develop preventive treatment avenues. The results of the study are published in the academic journal Cell Stem Cell.
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 11 October 2017.
Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.
UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.